Loading…

Efficacy of a Recombinant Glycoprotein D Subunit Vaccine on the Development of Primary and Recurrent Ocular Infection with Herpes Simplex Virus Type 1 in Mice

The protective efficacy of a glycoprotein D subunit vaccine (gD2 SB AS4) was evaluated in a mouse model of human recurrent herpetic stromal keratitis (HSK). When administered before primary infection, gD2 SB AS4 protected mice against corneal pathology, mortality, and latency resulting from ocular v...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1997-08, Vol.176 (2), p.331-338
Main Authors: Keadle, Tammie L., Laycock, Keith A., Miller, Judith Kelvin, Hook, Kelly K., Fenoglio, E. D., Francotte, Myriam, Slaoui, Moncef, Stuart, P. Michael, Pepose, Jay S.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The protective efficacy of a glycoprotein D subunit vaccine (gD2 SB AS4) was evaluated in a mouse model of human recurrent herpetic stromal keratitis (HSK). When administered before primary infection, gD2 SB AS4 protected mice against corneal pathology, mortality, and latency resulting from ocular viral challenge with herpes simplex virus type 1 (HSV-1) McKrae strain. In addition, gD2 SB AS4 significantly decreased postreactivation corneal disease. A control vaccine, gD2 alum, protected against acute ocular infection only. When administered after primary infection, gD2 SB AS4 vaccination decreased postreactivation ocular shedding but had no other significant effects. Vaccination with gD2 SB AS4 was associated with high anti-gD antibody responses and low delayed-type hypersensitivity responses. These results have identified a prophylactic vaccine, gD2 SB AS4, with activity against acute and recurrent HSK in mice and emphasize the need for vaccine evaluation in both primary and recurrent ocular herpetic disease models.
ISSN:0022-1899
1537-6613
DOI:10.1086/514049